Thaddeus Stappenbeck, MD, PhD
Lerner Research Institute,
9500 Euclid Avenue, Cleveland, Ohio 44195
Phone: (216) 444-3082
My lab is interested in discovering host and environmental factors that impact inflammation and wound repair at mucosal surfaces. These processes impact the pathogenesis of a number of disease states including inflammatory bowel disease. We use combinations of studies using human cells and tissues as well as mouse and in vitro models to approach these problems. The focal point of these studies is often the intestinal epithelial barrier. To make advances in this area, we have developed novel methods to model these cells under a variety of relevant conditions. We then study mechanisms by which the diet/microbiome as well as select stromal/immune cells impact this system. Our overarching goal is to understand combinations of genetic and environmental factors that affect specific epithelial cell function and thus predispose individuals to develop active intestinal inflammation.
The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites. Kaiko GE, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, Pearce EL, Oltz EM, Stappenbeck TS.
Cell. 2016 Nov 3;167(4):1137. doi: 10.1016/j.cell.2016.10.034
Researchers led by Thaddeus Stappenbeck, MD, PhD, chair of the Department of Inflammation & Immunity, have developed a new preclinical model with features of mesenteric fibrosis that are similar to what is found in Crohn’s disease patients (CD). Using clinical data coupled with the new model may help researchers identify new therapeutic targets to prevent or treat fibrosis in CD.
According to new study results, a team of researchers from multiple institutions and led by Cleveland Clinic’s Thaddeus Stappenbeck, MD, PhD, have found that a diet high in fat and sugar is associated with impaired intestinal immune cell function in mice. The findings, published in Cell Host & Microbe, provide novel insights into pathways linking obesity and disease-driving gut inflammation, and have implications for developing targets to treat inflammatory bowel diseases (IBD) in patients.
Researchers have characterized a new tissue infection in patients with Crohn’s disease (CD) and preclinical disease models. According to new study results published in Science, the yeast Debaryomyces hansenii—commonly found in foods such as cheese and processed meat—is significantly enriched in areas of intestinal injury in preclinical models and CD patients, a discovery that may point to new treatment or prevention approaches for the common inflammatory bowel disease.
Thaddeus (Thad) Stappenbeck, MD, PhD, joins Lerner Research Institute as the newly appointed Chair of the Department of Inflammation & Immunity. A digestive disease expert, he will lead a department of more than 50 principal investigators studying the origins and manifestations of a range of diseases, including infectious, autoimmune, and inflammatory diseases like asthma and transplant rejection.